Pfizer Receives Breakthrough Therapy Designation for Tafamidis for Rare Heart Condition

Pfizer Inc. (NYSE:PFE) announced on 5/22/18 that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with transthyretin cardiomyopathy, a rare, fatal, and underdiagnosed condition associated with progressive heart failure.